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Metachronous bilateral breast cancer – a comparison of clinical
and histopathological features of the first
and of the second primary cancer
Janusz Piekarski
I n t r o d u c t i o n.  Bilateral breast cancer (BBC) is recognised in patients, who develop two primary tumors in both breasts.
Cancer metastases to the contralateral breast are not considered as BBC. BBC may be diagnosed as a synchronous or
a metachronous disease.
This study compares clinical and histopathological features of the first and the second BBC.
M a t e r i a l  a n d  m e t h o d s. 3646 women with breast cancer were operated upon at the Department of Surgical Oncology,
Medical University of ¸ódê, between 1977 and 1998. BBC was recognised in 139 of them (3.81%), of which 99 (2.71%) we-
re metachronous (MBBC) – i.e. the interval between two diagnoses was at least six months. The final analysis was performed
on a group of 74 women with MBBC. The remaining 25 women were excluded from the study due to incomplete data concer-
ning the first cancer.
Results. The interval between the diagnosis of the first and of the second cancer ranged from 7 to 293 months (mean 70.7 mon-
ths). The mean duration of the symptoms before the diagnosis of the first MBBC (fMBBC) was significantly longer than be-
fore the diagnosis of the second MBBC (sMBBC) (5.8 months fMBBC vs 3.0 months sMBBC; p<0.05). The mean diame-
ter of the first tumor (fMBBC) was significantly larger, than that of the second (sMBBC) (4.8 cm fMBBC vs 3.1 cm sMBBC;
p<0.05). Local stage (T) of fMBBC was higher than local stage of sMBBC (p<0.05). Regional stage of both cancers (acc. to
the clinical TNM scale) was similar. In 28 of the 74 patients (37.8%) the histological type of the first cancer was different
from that of the second. In the remaining 46 patients (62.2%) the histologic types of both cancers were the same. There we-
re no in situ cancers among sMBBC. The percentage of fMBBC and sMBBC cases with lymph nodes metastases was the sa-
me (43.2%).
C o n c l u s i o n s. (1) In patients with MBBC the second cancers were significantly smaller then the first. The duration of symp-
toms before the diagnosis of the second cancer was shorter. However, axillary lymph nodes metastases were found in the sa-
me percentage of cases of fMBBC and sMBBC. (2) Our observations confirm that routine mammographic screening of con-
tralateral breast in women with diagnosed unilateral breast cancer is of crucial importance. Contralateral mammography sho-
uld be performed every 12-18 months after breast cancer surgery throughout the patients' life.
Dwuczasowy obustronny rak piersi – porównanie cech klinicznych
i patologicznych pierwszego i drugiego raka
W p r o w a d z e n i e.  Obustronny rak piersi (ORP) jest rozpoznawany u kobiet, u których rozwin´∏y si´ dwa pierwotne raki
w obu piersiach. Przerzuty raka wyst´pujàcego jednostronnie do drugiej piersi nie sà uznawane za ORP. ORP mo˝e ujawniç
si´ w postaci choroby jednoczasowej lub dwuczasowej.
C e l. Porównanie cech klinicznych i histopatologicznych pierwszego i drugiego ORP.
M a t e r i a ∏  i m e t o d y.  W latach 1977-1998 w Klinice Chirurgii Onkologicznej Akademii Medycznej w ¸odzi operowano
3646 kobiet z powodu raka piersi. U 139 z nich (3,81%) rozpoznano obustronnego raka piersi. U 99 (2,71%) choroba
mia∏a postaç dwuczasowà, to znaczy drugiego raka rozpoznano po up∏ywie co najmniej 6 miesi´cy od rozpoznania pierwsze-
go raka. Dane kliniczne i histopatologiczne na temat pierwszego i drugiego raka uzyskano z historii chorób Regionalnego
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List of abreviations:
BBC – bilateral breast cancer
SBBC – synchronous bilateral breast cancer
MBBC – metachronous bilateral breast cancer
fMBBC – first metachronous bilateral breast cancer
sMBBC – second metachronous bilateral breast cancer
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Introduction
Breast cancer is the most common malignancy in women
in developed countries [1]. It may develop as a unilateral
or a bilateral disease. Bilateral breast cancer (BBC) is
recognised in women, in whom two primary tumors are
diagnosed in both breasts. Cancer metastases to the con-
tralateral breast are not classified as BBC. The first case
of bilateral breast cancer was reported as early as in 1800
by William Nisbet [3]. The revolution in breast cancer
therapy occured almost one hundred years later, when
in 1882 Halsted resected a cancerous breast en block with
both pectoral muscles and axillary lymph nodes [4]. This
led to a significant increase of survival – in the 1920s five-
-year survival reached 30%. However a number of survi-
vors developed new primary cancer in the contralateral
breast. The first major paper on bilateral breast cancer
was published in 1921 [5].
Bilateral breast cancer may be diagnosed as a syn-
chronous or a metachronous disease. Synchronous BBC
is recognised when the second, contralateral tumor is
not found later than six months after the diagnosis of
the first cancer. Metachronous cancer is diagnosed when
the period between the diagnosis of the first and the se-
cond cancer exceeds 6 months [6-9]. It should be noted
that these terms are not biological, but purely clinical,
while the classification bases only upon the time inte-
rval between the diagnoses of the first and the second
cancer. As the natural history of breast cancer may exce-
ed 10 years before the tumour reaches the volume of 1
cm3 [10], one should be aware that clinically metachrono-
us cancers may, in fact, be biologically synchronous. The
development of imaging techniques, especially the in-
troduction of routine contralateral mammography in the
1980s, increased the incidence of metachronous BBC 5-
-fold [11].
The diagnosis of a malignant tumor in the breast of
a patient previously treated for cancer of the contralateral
breast raises a fundamental question: is the diagnosed
lesion a new primary cancer, or is it a metastatic tumor
from the contralateral breast? The answer is crucial, as it
implies the type of treatment to be introduced. Clinical
and pathological criteria for diagnosing second primary
cancer that have been outlined by Robbins and Berg
(1964) [12], Haagensen (1971) [13] and Chaudary (1984)
[11] are important. When combined and considered, they
are a useful clinical tool, and allow for the correct selec-
tion of women with two primary cancers in both breasts.
These crieria may be presented as follows: (1) due to
a typical spread of cancer across the midline to the second
breast, it can well be expected that metastatic lesions are
predominantly located in the inner quadrants of the con-
tralateral breast. (2) metastatic lesions are usually multi-
ple. Generally, the second primary cancers are solitary. (3)
when cancer spreads to the second breast distant metasta-
ses are usually present. They are usually absent if the tu-
mor in the contralateral breast is a new primary cancer.
(4) the typical location of metastatic tumors is in the fat
surrounding the breast parenchyma. New primaries are
located within the parenchyma. (5) New cancers infiltra-
te the surrounding tissues; metastases expand them. (6)
The tumour in the second breast is a new primary cancer
if carcinoma in situ is discerned. (7) The tumor of the
contralateral breast is a new primary if its histologic type
is different from that of the first breast cancer. (8) The
cancer in the second breast is to be considered a new pri-
mary if its degree of histological differentiation is distinc-
tly greater than that of the lesion in the first breast. (9) If
these criteria are not met, the second tumor can be consi-
dered the new primary provided there is no evidence of
local, regional or distant metastases from the cancer of
the ipsilateral breast.
OÊrodka Onkologicznego. Badaniami obj´to ostatecznie 74 kobiety, które oba zabiegi operacyjne mia∏y wykonane w Klinice.
Pozosta∏e 25 kobiet wy∏àczono z badaƒ z powodu niepe∏nej dokumentacji dotyczàcej pierwszego raka.
W y n i k i. Odst´p czasowy mi´dzy wystàpieniem pierwszego i drugiego raka waha∏ si´ od 7 do 293 miesi´cy; Êrednio 70,7 mie-
siàca. Âredni czas trwania objawów chorobowych przed rozpoznaniem pierwszego dwuczasowego obustronnego raka piersi
(pDORP) by∏a znaczàco d∏u˝szy od Êredniego czasu trwania objawów przed rozpoznaniem drugiego dwuczasowego obustron-
nego raka piersi (dDORP) (5,8 miesiàca pDORP w porównaniu do 3,0 miesi´cy dDORP; p<0,05). Ârednia Êrednica pierw-
szego raka (pDORP) by∏a znaczàco wi´ksza ni˝ Êrednia Êrednica drugiego raka (dDORP) (4,8 cm pDORP w porównaniu do
3,1 cm dDORP; p<0,05). Stan zaawansowania regionalnego (w skali TNM) obu raków by∏ podobny. U 28 spoÊród 74 cho-
rych (37,8%) typ histologiczny pierwszego raka ró˝ni∏ si´ od typu drugiego raka. U pozosta∏ych 46 chorych (62,2%) typ histo-
logiczny obu raków by∏ taki sam. WÊród dDORP nie stwierdzono ˝adnego raka in situ. Przerzuty do w´z∏ów ch∏onnych rozpo-
znano u takiego samego odsetka chorych na pDORP, jak i dDORP (43,2%).
W n i o s k i. 1. Raki drugiej piersi u kobiet chorych na dwuczasowego obustronnego raka piersi by∏y znaczàco mniejsze ni˝
pierwsze raki. Czas trwania objawów chorobowych przed rozpoznaniem drugiego raka by∏ krótszy ni˝ przed rozpoznaniem
pierwszego raka. Mimo to, przerzuty w pachowych w´z∏ach ch∏onnych stwierdzono u takiego samego odsetka chorych przy roz-
poznaniu pierwszego raka, jak i przy rozpoznaniu drugiego raka. 2. Nasze obserwacje potwierdzi∏y, i˝ rutynowe wykonywanie
mammografii drugiej piersi u kobiet chorych na jednostronnego raka piersi ma znaczenie podstawowe. W ramach poopera-
cyjnych badaƒ kontrolnych kobiet chorych na raka piersi, mammografi´ drugiej piersi powinno si´ wykonywaç co 12-18 mie-
si´cy przez ca∏e ˝ycie chorych.
Key words: metachronous, bilateral, breast cancer
S∏owa kluczowe: dwuczasowy, obustronny, rak piersi
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Our study material was qualified according to these
criteria
Aim of the study
To compare the clinical and pathologic features of the
first and the second cancer in women with metachronous
bilateral breast cancer.
Material and methods
Between 1977 and 1998 3646 women underwent surgical treat-
ment for breast cancer at the Clinical Department of Surgical
Oncology of the Medical University of ¸ódê. Bilateral breast
cancer was diagnosed in 139 cases (3.81%). In 99 cases (2.71%)
the disease was metachronous, i.e. the second cancer was not
diagnosed earlier than six months after the first. Clinical and
histologic data concerning both breasts was obtained from the
patients' files at the Regional Oncologic Center. Data analysis
comprised: (1) the age at the diagnosis of the first and the se-
cond breast cancer; (2) the duration of symptoms; (3) the inte-
rval between the diagnosis of each lesion of the pair; (4) the
clinical features of the tumours (diameter, TNM-staging, loca-
tion); (5) the pathology of the tumors (histologic type, grade,
multicentricity, nodal status). A retrospective review of the files
provided complete clinical and pathological data of 74 women.
The remaining 25 women with metachronous BBC underwent
initial surgery outside our Department and, unfortunately, the
data concerning the first tumour was incomplete. These 25 pa-
tients were excluded from further study. Statistical analysis was
performed using the Student t test and χ2 test; p values less
than 0.05 were considered to be significant.
Results
The age of the patients, duration of symptoms before dia-
gnosis, location, size and stage (TNM) of the first and the
second cancers are presented in Table I. Pathological fe-
atures of the tumours are listed in Table II. Data concer-
ning diagnostic and surgical procedures is presented in
Table III.
The time interval between the diagnosis of the first
and the second cancer ranged between 7 and 293 mon-
ths (mean 70.7 months (SD 60.1; median 49.5)). (Fig. 1)
The mean duration of symptoms before the diagnosis of
the first MBBC (fMBBC) was significantly longer than
before the diagnosis of the second MBBC (sMBBC)
(5.8 months fMBBC vs 3.0 months sMBBC; p<0.05).
The mean diameter of the first tumor was significantly
greater than the mean diameter of the second tumor
(4.8 cm fMBBC vs 3.1 cm sMBBC; p<0,05). There were
no significant differences in the location of the first and
the second tumors (side, quadrants). The local stage
(T) of fMBBC was higher than the local stage of
sMBBC. The difference was statistically significant. The
regional stage of the cancers (according to the TNM
scale) was similar.
The results of cytological examination revealed the
presence of cancer cells in a similar percentage of cases in
both groups. Suspected cells were found in a higher per-
centage of cytology specimens obtained from patients
Tab. I. First and second metachronous bilateral breast cancer – clinical data
fMBBC sMBBC
Age (years) 49.3±12.1 55.0±11.6
Duration of symptoms (months) 5.8±8.2 3.0±2.7
Localization of cancer on side: (%)
- left 35 (47.3) 39 (52.7)
- right 39 (52.7) 35 (47.3)
Localization of cancer in quadrant (%)
- upper-outer 25 (33.8) 23 (31.1)
- upper quadrants' border 11 (14.9) 14 (18.9)
- central 10 (13.5) 10 (13.5)
- outer quadrants' border 10 (13.5) 13 (17.6)
- upper-inner 5 (6.8) 4 (5.5)
- lower quadrants' border 5 (6.8) 6 (8.1)
- lower-outer 4 (5.4) 1 (1.3)
- lower-inner 3 (4.0) 2 (2.7)
- inner quadrants' border 1 (1.3) 1 (1.3)
Tumor's diameter (cm) 4.8±2.5 3.1±1.5
Stage of primary tumor classified clinically – T (%)
- T0 0 (0) 3 (4.1)
- T1 8 (10.8) 16 (21.6)
- T2 35 (47.3) 45 (60.8)
- T3 17 (23.0) 4 (5.4)
- T4 14 (18.9) 6 (8.1)
Stage of regional lymph nodes (clinically) – N (%)
- N0 35 (47.3) 44 (59.5)
- N1 30 (40.5) 24 (32.4)
- N2 9 (12.2) 6 (8.1)
Data are presented as: mean value ± standard deviation; number of patients (percentage). fMBBC means:
first metachronous bilateral breast cancer; sMBBC means: second metachronous bilateral breast cancer
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with sMBBC than from patients with fMBBC (fMBBC
8.1% vs sMBBC 17.6%; p<0.05). The examined cells we-
re considered normal in a significantly higher percentage
of fMBBC specimens, than sMBBC specimens (fMBBC
6.8% vs sMBBC 1.3%; p<0.05).
Preoperative chemotherapy was given in a higher
percentage of the first MBBC than of the second MBBC
(fMBBC 24.3% vs sMBBC 5.4%; p<0.05). Frozen sec-
tion examination was performed in a similar percentage
of cancers. Surgical treatment was similar in both can-
cers.
The percentages of invasive ductal, lobular in situ
and ductal in situ cancers were similar both groups. Inva-
sive lobular cancer was more rare among the first MBBC
than among the second MBBC patients (I MBBC 10.8%
vs II MBBC 27.0%; p<0.05).
The grade of invasive cancers was not compared be-
tween the groups, as changes after chemotherapy preclu-
ded grading in a majority of cases.
In 28 of 74 patients (37.8%) the histologic type of the
first cancer was different from the type of the second
cancer. In the remaining 46 patients (62.2%) the histolo-
gic type of both cancers was the same. The difference
between the mean number of removed lymph nodes was
not significant. Similarly, there was no significant differen-
ce between the mean number of cancer-positive nodes
in both groups. The percentage of the first MBBC cases
with cancer-positive nodes was the same as the percenta-
ge of the second MBBC cases (43.2%). Infiltration of
node capsule, cancer cells emboli and multifocality/multi-
centricity was observed in a similar percentage of patients
in both groups (p>0.05).
Tab. II. First and second metachronous bilateral breast cancer – results of pathologic examination
fMBBC sMBBC
Type of cancer (%)
- ductal invasive 62 (83.8) 54 (73.0)
Grade 1 – Bloom and Richardson scale 3 (4.1) 4 (5.4)
Grade 2 – Bloom and Richardson scale 16 (21.6) 10 (13.5)
Grade 3 – Bloom and Richardson scale 24 (32.4) 31 (41.9)
Grade was not evaluated due to damage of cancer cells 
after chemotherapy 14 (18.9) 2 (2.7)
- lobular invasive 8 (10.8) 20 (27.0)
- ductal cancer in situ 2 (2.7) 0 (0)
- lobular cancer in situ 0 (0) 0 (0)
- mixed type 2 (2.7) 0 (0)
Mean number of cancer-positive axillary lymph nodes 2.1±4.1 1.9±3.9
Metastases in axillary lymph nodes (%) 32 (43.2) 32 (43.2)
Infiltration of node's capsule (%) 10 (13.5) 17 (23.0)
Emboli of cancer cells (%) 8 (10.8) 9 (12.1)
Multifocality/multicentricity (%) 7 (9.5) 5 (6.8)
Data are presented as: mean value ± standard deviation; number of patients (percentage). fMBBC means:
first metachronous bilateral breast cancer; sMBBC means: second metachronous bilateral breast cancer
Tab. III. Diagnostic procedures, adjuvant therapy and type of surgery in patients with first and second
metachronous bilateral breast cancer
fMBBC sMBBC
Results of cytological examination (%)
- cancer cells 63 (85.1) 60 (81.1)
- suspected cells 6 (8.1) 13 (17.6)
- normal cells 5 (6.8) 1 (1.3)
Frozen section examination 11 (14.9) 14 (18.9)
Preoperative chemotherapy 18 (24.3) 4 (5.4)
Type of surgery
- modified radical mastectomy – Madden type 69 (93.3) 71 (96.0)
- radical mastectomy – Halsted type 1 (1.3) 0 (0)
- quadrantectomy 2 (2.7) 1 (1.3)
- total (simple) mastectomy 2 (2.7) 2 (2.7)
Mean number of removed lymph nodes 10.0±4.6 11.1±4.1
Data are presented as: mean value ± standard deviation; number of patients (percentage). fMBBC means:
first metachronous bilateral breast cancer; sMBBC means: second metachronous bilateral breast cancer
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Discussion
The analysis of our material revealed 139 cases (3.81%) of
bilateral breast cancer. In 40 of these cases (1.1%) contra-
lateral cancer was found synchronously with the first can-
cer (SBBC), i.e. the diagnosis of both cancers was made
simultaneously, or the second cancer was not diagnosed
later than 6 months after the first one. In the remaining
99 cases (2.71%) metachronous bilateral breast cancer
was recognised (MBBC). Patients with synchronous BBC
comprised 29.6% and patients with metachronous BBC
70.4% of all BBC patients.
Literature reports varying results. The percentage of
BBC patients ranges, among all breast cancer patients, be-
tween 2.4% and 20% [8, 14-26]. This percentage depends
mainly on the duration of the follow-up after surgery. The
longer this period, the higher the number of contralateral
cancers may develop in the studied population of unilateral
breast cancer patients. The proportion of metachronous
cancers to synchronous cancers also changes: the shorter
the follow-up period, the higher the percentage of meta-
chronous cancers [27]. Synchronous BBC is recognised in
0,3-3% of patients with breast cancer [6-8, 11, 14, 15, 19, 20,
28-31]; metachronous BBC is recognised in 2.6%-11.8% of
breast cancer patients [8, 14, 15, 17, 22]. The presented
incidence of BBC cancers was observed in patients in
whom contralateral cancers were detected mammographi-
cally or during physical examination. In patients in whom
contralateral breast biopsies or prophylactic contralateral
mastectomies were performed, the incidence of synchrono-
us BBC detected in histopathologic examination, was even
as high as 50% [32-40]. However, the majority of such con-
tralateral neoplasms are ductal in situ or lobular in situ
cancers. Invasive cancers do not exceed 7.7% of all syn-
chronous BBC [32-40]. The percentage of contralateral
cancers found in patients after prophylactic mastectomies
and in some autopsy studies [41], substantially exceeds the
incidence found in clinical studies [42]. It seems that at le-
ast some contralateral cancers regress or, during a pa-
tient's lifetime, do not reach sizes allowing for their clinical
or mammographical detection [11, 41].
The proportion of synchronous to metachronous
BBC depends mainly on the type of contralateral breast
screening in patients with unilateral disease. Studies con-
ducted before the 1980s studies comprised patients in
whom mammography was practically not performed. In
those studied the percentage of synchronous BBC did
not exceed 15% of all BBC patients [12, 13, 25]. Routine
mammographic screening of the contralateral breast, in-
troduced in late 1970s, allowed to detect a majority of
nonpalpable breast cancers. Had mammography not been
performed, these contralateral cancers would have been
detected clinically during the first 3 years of follow-up
after the first surgery, and therefore, be pronounced as
metachronous. With the introduction of mammography as
a non-obligatory part of contralateral breast screening,
the percentage of synchronous BBC reached 25%-30% [8,
26, 43, 44]. Nowadays, when mammography of the contra-
lateral breast is a routine diagnostic procedure, the pro-
portion of synchronous to metachronous BBC appro-
aches one [9, 14, 16, 27, 45]. However, it must be stressed
that although routine mammographic screening of the
contralateral breast has increased the detectability of syn-
chronous BBC, the total detectability of bilateral breast
cancer has remained stable [15].
The percentage of synchronous BBC patients among
all BBC patients treated in our Clinic (29.6%) is nearest
to the observations of Yeatman et al. (29.3%) [44], Schell
et al. (30.9%) [43] and studies performed by Senofsky et
al. between 1976 and 1984 (28%) [25]. Also, Ku∏akowski
et al. observed that synchronous BBC comprised 32.3% of
all BBC patients [26]. However, in studies by Ku∏akowski,
synchronous BBC was recognised when both cancers we-
re diagnosed within a 3-month time intrerval (in our stu-
dy this interval was set at 6 months).
In our study, a majority of the first metachronous
BBCs were diagnosed in the fifth decade of life (40-49
y.a.). The mean age at the time of the diagnosis of the first
MBBC was 49.3. The diagnosis of the second MBBC was
most prevalent in the sixth decade of life (50-59 y.a.).
The mean age at the diagnosis of the second MBBC was
55.0 (Fig. 2). Our observations resemble those of other
authors. The mean age of patients at the time of diagno-
sis of the first MBBC is generally reported to be less
than50 [6, 11, 46, 47], while in the case of the second
MBBC the usual age is over 50 years [46, 47].
Fig. 1. Age of patients at the time of diagnosis of the first and second
metachronous bilateral breast cancer
Fig. 2. Time interval between diagnoses of the first and second bilate-
ral breast cancer
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The mean interval between the diagnosis of the first
and the second metachronous BBC in patients treated
in our Clinic was 5 years and 11 months (70.7 months).
The reported time intervals between these two diagnoses
ranges between 4.5 years to 9.7 years [8, 26, 27, 46-48].
Egan et al. observed that 85% of contralateral cancers
were recognised within 6 years from the diagnosis of the
first cancer [46]. We have observed similar results, as
78% of contralateral cancers in our BBC patients were re-
cognised during the first 6 years of follow-up after the
first diagnosis, while the longest time interval between
the two diagnoses was 26 years. In the studies of Egan et
al. the longest time interval between the two diagnoses
was similar, reaching 27 years [46].
In our patients we have observed a peak of inci-
dence of the second metachronous BBC during the first
three years of follow-up (Fig. 2). The morbidity caused
by of contralateral cancer was twice as high during the
second and third year of follow-up as during all next
years of follow-up. Similar observations were reported in
studies performed before 1980. Those studies had shown
that the morbidity caused by contralateral cancer du-
ring the second year [17], the second and third year [12,
49], and the second, third and fourth year [30] after the
diagnosis of the first cancer was twice as high, as the
morbidity caused by contralateral cancer during all the
next years. A majority of contralateral cancers would
have been diagnosed synchronously with the first breast
cancer, had mammography of the contralateral breast
been performed at the time of the diagnosis of the first
cancer.
We did not observe any statistically significant diffe-
rence between the percentage of the first cancers loca-
ted in the left or in the right breast. In a majority of ca-
ses both the tumours were located in the upper-outer
quadrant and centrally in the subareolar tissue. There
were no statistically significant differences between
the groups concerning the anatomical location of the
tumour.
The mean diameter of the first metachronous tu-
mor was significantly larger than the mean diameter of
the second tumor (4.8 cm vs 3.1 cm). Therefore, the local
stage (T – in TNM scale) of the first cancer was higher,
than that of the second cancer. However, locoregional
stage of the first cancer was similar to that of the second
cancer. In both groups the axillary lymph nodes were pal-
pable in a similar percentage of patients. Clinical observa-
tion was confirmed by histopathology. In both groups
metastases were found in an identical percentage of pa-
tients (i.e. 32/74; 43.2%).
There was no difference between the groups as to
the mean number of cancer-positive lymph nodes (first
metachronous BBC 2.1 vs second metachronous BBC
1.9). In conclusion, although the first tumors were lar-
ger than the second tumors, the regional stage of the first
and the second BBC was the same.
Other authors report varying data concerning the
stage of the first and the second metachronous cancers.
Some of the authors have found that the stages of the
first and the second BBC were the same [8, 17, 50-53]. We
have paid special attention to the results of Fisher et al.
[17]. In their population of metachronous BBC patients,
contralateral tumors were smaller than the first tumors,
but the percentage of cases with metastases in axillary
lymph nodes was the same in both groups. We have found
that our results are closest to those of Fisher et al. Other
authors have reported different results; for instance the
second cancers were less advanced than the first ones
[12, 14, 25, 27, 46, 48, 54]. Senofsky et al. [25] performed
a comparison of two consecutive groups of patients with
BBC, the main difference lying in the fact that the first
group was treated a decade earlier than the second. Seno-
fsky has reported, that the diagnosis of the second cancer
at an earlier stage than the first cancer, had not been po-
ssible before the introduction of routine mammographic
screening of the contralateral breast. However, the obse-
rvations of Robbins and Berg published in 1964 negate
such a conclusion [12] stressing that the second cancers
were less advanced than the first ones, although mam-
mography was not perfomed in their BBC patients. Ro-
binson et al. [48] have shown that in patients in whom
follow-up contained a thorough and regular physical exa-
mination, the second cancers were significantly smoller
and metastases to axillary lymph nodes were significantly
more rare than in the case of patients who did not under-
go regular examination. It may, therefore, be surprising,
that the survival was similar in both groups. It seems that
palpation of the contralateral breast is not sufficient as
a follow-up procedure in order to decrease the mortality
in patients with metachronous BBC. Introducing mammo-
graphy into routine practice has decreased the mortality
of patients with unilateral breast cancer. It is suggested
that mammography screening of the contralateral breast
of breast cancer patients will decrease the mortality of
women with metachronous BBC [48].
The stages of the first and the second BBC corre-
sponded with the duration of symptoms before diagnosis.
The mean duration of symptoms in patients with the first
metachronous cancer was 5.8 months. Contralateral can-
cers were diagnosed earlier. The mean duration of symp-
toms was 3.0 months. It seems that women treated for
unilateral breast cancer were more aware of the symp-
toms of the disease. Moreover, some contralateral cancers
were diagnosed during follow-up examinations.
In our patients contralateral cancers were smaller
than the first cancers and the symptoms lasted shorter
before the diagnosis of contralateral cancers. However,
the regional stage of both cancers was the same. Our ob-
servations confirm that regular mammographic follow-
-up performed every 12-18 months is necessary for earlier
diagnosis of contralateral breast cancer in women with
unilateral cancers
The number of patients with the second metachrono-
us BBC who had received preoperative chemotherapy
(5.4%) was lower than the number of chemotherpy pa-
tients with the first cancer (24.3%). It may be presumed
that the reasons for this were: (1) the second tumors we-
re significantly smaller than the first tumors; consequen-
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tly chemotherapy was not necessary as often as before
the first surgery; (2) many patients had already been given
chemotherapy before or after the first surgery. The mode
of surgical treatment of the first and contralateral cancers
was similar (difference of no statistical significance).
Cytological examination results revealed the pre-
sence of cancer cells in a similar percentage of cases in
both groups (the first MBBC – 85.1%; second MBBC –
81.1%). Consequently, in a similar percentage of pa-
tients, the diagnosis of cancer was made during frozen
section examination following wide local resection of
the suspected tumor (first MBBC 14.9%; second MBBC
18.9%). It may be worth stressing that suspected cells
were found in higher percentage of cytology specimens
of patients with second MBBC than patients with the
first MBBC (first MBBC 8.1%; second MBBC 17.6%).
It is likely that cytologists were aware of elevated risk of
contralateral cancer in women previously treated for
unilateral disease, and, therefore, cells were referred to
as suspected even if only slight abnormalities were ob-
served.
In 37.8% of our patients with metachronous bilateral
breast cancer, the histologic type of the first and the se-
cond cancers differed. A similar percentage was reported
by Gogas et al. – 37.2% [8]. Lesser values were observed
by Khafagy et al. (25%) [52].
The percentage of invasive lobular cancers among
the first metachronous BBC in our patients (10.8%) is si-
milar to that reported in literature (7.6%-8.5%) [52,
55]. Khafagy et al. [52] have observed that the percenta-
ge of lobular cancers among the second metachronous
BBC (13.4%) is higher than among the first cancers
(8.5%). This correlates with our results. However, in
our patients the percentage of invasive lobular cancers
among the second MBBC is surprisingly high. It was al-
so surprising that not once did we find lobular in situ
cancers. Neither did we find intraductal cancers among
the second metachronous cancers (0%). Some authors
have reported that when physical examination is used,
intraductal cancers comprise 4-5% of all the second me-
tachronous BBC [7, 56], while if mammography is also
used in some cases, this percentage increases to about
20% [57]. Routine contralateral screening allows for
further increase of this value. Roubidoux et al. [57] have
found that intralductal cancers comprise 41% of all con-
tralateral metachronous cancers. Among all contrala-
teral metachronous BBC detected by mammography,
in situ cancers comprised 56%. These facts strongly indi-
cate that the follow-up of our patients with unilateral
cancer was not sufficient.
Conclusions
1. Second cancers of the breast in women with metachro-
nous bilateral breast cancer were significantly smaller
then the first ones. The duration of symptoms before
the diagnosis of the second cancer was shorter than
before the diagnosis of the first ones. Nevertheless,
metastases in axillary lymph nodes were found in the
same percentage of women with the first breast cancer
as women with the second breast cancer.
2. Our observations confirm that routine mammographic
screening of the contralateral breast in women with
diagnosed unilateral breast cancer is of crucial impor-
tance. Patients treated for breast cancer should un-
dergo contralateral mammography every 12-18 months
throughout their life.
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